Lv1
78 积分 2023-02-10 加入
Bevacizumab plus erlotinib in advanced solid cancers with Krebs cycle gene mutations: A multicenter phase II study (BRISK; KCSG AL22-16)
1个月前
已完结
The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
1个月前
已关闭
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer
1个月前
已完结
MA04.09 Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN
1个月前
已关闭
Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas
1个月前
已完结
MA04.09 Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN
1个月前
已关闭
OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer
1个月前
已完结
Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
2个月前
已完结
MA04.09 Patterns of Progression and Recurrence with Perioperative Durvalumab in Patients with Resectable NSCLC from AEGEAN
2个月前
已关闭
De Novo Germline L858R EGFR Variants and Generalized Acanthosis Nigricans
2个月前
已完结
皖公网安备34019202002308
